Peer reviewed
Cardiovascular outcomes with tirzepatide versus dulaglutide in Type 2 diabetes
SURPASS-CVOT publication reporting that tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events in adults with Type 2 diabetes and established atherosclerotic cardiovascular disease.
National Library of MedicinePublished 2025-12-18Accessed 2026-07-12
Registry record
Source metadata
- Publisher
- National Library of Medicine
- Source type
- Peer reviewed
- Registry ID
pubmed-surpass-cvot-2025- DOI
- 10.1056/NEJMoa2505928
- PMID
- 41406444
Source usage
Linked from 2 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.